Has Rolan Pascual, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,531 in general payments to Rolan Pascual, MD across 160 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rolan Pascual, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rolan Pascual, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rolan Pascual, MD

Medical Oncology · Mishawaka, INNPI 1518961002

Payments from drug & device makers

$3,531in general payments, 2019–2025

Across 160 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$313
Merck$310
E.r. Squibb & Sons, L.L.C.$214
AstraZeneca$213
Amgen$188
Johnson & Johnson$148
plus $2K from 38 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	10	$313
Merck	18	$310
E.r. Squibb & Sons, L.L.C.	10	$214
AstraZeneca(2 entities)	11	$213
Amgen	15	$188
Johnson & Johnson	1	$148
Pfizer	10	$143
Genentech USA, Inc.	5	$140
Inspire Medical Systems, Inc.	1	$122
Sanofi-aventis U.S. LLC	2	$118
Sanofi	6	$113
Seagen Inc.	1	$99
Bristol Myers Squibb	5	$89
Daiichi Sankyo Inc.	4	$87
Gilead	4	$83
Pharmaessentia USA Corporation	4	$81
Regeneron Healthcare Solutions, Inc.	4	$81
GSK	3	$75
Tempus AI, Inc	3	$71
Deciphera Pharmaceuticals Inc.	4	$70
Takeda Pharmaceuticals U.S.A., Inc.	2	$67
Jazz Pharmaceuticals Inc.	2	$64
Incyte Corporation	3	$63
Astellas Pharma US Inc	3	$62
Beone Medicines USA, Inc.	2	$51
AbbVie(2 entities)	3	$44
Verastem, Inc.	2	$43
Acrotech Biopharma Inc.	3	$43
Pharmacyclics LLC, An Abbvie Company	2	$39
Adaptive Biotechnologies Corporation	1	$27
Foundation Medicine, Inc.	2	$27
Eisai Inc.	2	$27
Rigel Pharmaceuticals, Inc.	1	$22
Puma Biotechnology, Inc.	1	$21
Genmab U.S., Inc.	1	$21
Coherus Oncology, Inc.	1	$21
AVEO Pharmaceuticals, Inc.	1	$20
Stemline Therapeutics Inc.	1	$19
Recordati_rare_diseases_inc.	1	$18
Boehringer Ingelheim	1	$18
Exelixis Inc.	1	$16
Iovance Biotherapeutics, Inc.	1	$16
Taiho Oncology, Inc.	1	$14
Pharmaand GmbH	1	$10

How this compares

$3,531 in reported general payments places this provider in the 35th percentile of 67 medical oncology providers in Indiana.

See all medical oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$1,323,897

Medicare patients

436

Services billed

82,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Mishawaka

Rafat AnsariMishawaka$90K
Robin ZonMishawaka$12K
Bilal AnsariMishawaka$9K
Rashid KhanMishawaka$6K
Jose BufillMishawaka$3K
Sayuri CheruvuMishawaka$2K
Sunil BabuFort Wayne$12.5M
Bert OneilIndianapolis$7.6M
Natraj AmmakkanavarIndianapolis$4.1M
Takefumi KomiyaFort Wayne$2.8M

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →